Lexicon Pharmaceuticals Nachrichten und Aktivitäten

Lexicon Pharmaceuticals ist einer der ...

• Russell 3000;
• TOB Iconic 10,000.

Lexicon Pharmaceuticals ist ein Unternehmen, das unter dem Börsenticker LXRX (US) gelistet ist.

Siehe das Organigramm mit seine 25 wichtigsten Führungskräfte

Die meist gesuchten Biographien bei Lexicon Pharmaceuticals

• Mike Exton, Chief Executive Officer and Director
• Diane Sullivan, Director
• Raymond Debbane, Chairman of the Board

Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Lexicon Pharmaceuticals nachzuverfolgen.

Lexicon Pharmaceuticals hat 2.428 Konkurrenten , einschließlich Lonza (Schweiz), Vertex Pharmaceuticals (USA) und Eurofins (Luxemburg).

Popular M&A news in Biotechnologie

• Eli Lilly has announced the acquisition of AtaiBeckley  (veröffentlicht am 17, Juli 2026).
• GSK hat Nuvalent erworben (veröffentlicht am 17, Juli 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (veröffentlicht am 15, Juli 2026).

Andere vorgeschlagene Kontakte der Biotechnologie branche

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer bei Inceptive
• Jan Van de Winkel - President and Chief Executive Officer bei Genmab
• Patrick Enright - Director bei CuraSen Therapeutics

Mehr über die Biotechnologie branche erfahren

Neueste Pressemitteilungen nach Lexicon Pharmaceuticals

• Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
• New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
• Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
• Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
• New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
• Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
• Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
• Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
• Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
• Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
• View more press releases Close

Social media about Lexicon Pharmaceuticals

• Lexicon Pharmaceuticals auf Wikipedia, Google News & Yahoo Finance
• Lexicon Pharmaceuticals auf LinkedIn, X (Twitter) & YouTube